Clinical Trials Logo

Clinical Trial Summary

The purpose of this trial is to demonstrate the clinical efficacy, safety and tolerability of secukinumab compared to placebo in patients with ankylosing spondylitis at Week 16 and long term efficacy and safety up to Week 52.

Clinical Trial Description


Study Design

Related Conditions & MeSH terms

NCT number NCT02896127
Study type Interventional
Source Novartis
Status Active, not recruiting
Phase Phase 3
Start date October 18, 2016
Completion date March 21, 2019

See also
  Status Clinical Trial Phase
Active, not recruiting NCT01583374 - Study of Apremilast to Treat Subjects With Active Ankylosing Spondylitis Phase 3
Recruiting NCT02634541 - Adalimumab in Alleviating Inflammation in Patients With Axial Spondyloarthritis Phase 4